SINTX Technologies (SINT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
12 Jun, 2026Executive summary
Annual meeting scheduled for December 19, 2024, in a virtual-only format, with shareholders able to vote electronically before or during the meeting.
Five proposals will be presented: election of one Class I director, ratification of the auditor, advisory vote on executive compensation, amendment to the equity incentive plan, and potential adjournment to solicit more proxies.
Shareholders of record as of November 6, 2024, are entitled to vote; quorum is one-third of outstanding shares.
Voting matters and shareholder proposals
Proposal 1: Elect Mark Froimson, M.D. as Class I director for a term expiring in 2027.
Proposal 2: Ratify Tanner LLC as independent auditor for 2024.
Proposal 3: Advisory (non-binding) vote to approve executive compensation (say-on-pay).
Proposal 4: Approve amendment to 2020 Equity Incentive Plan, increasing authorized shares by 333,650.
Proposal 5: Approve adjournment of the meeting to solicit additional proxies if needed.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board consists of five members divided into three staggered classes; majority are independent under Nasdaq rules.
Committees: Audit, Compensation, and Corporate Governance/Nominating, all comprised of independent directors.
Board diversity matrix: all male, one Asian, four White; no female or underrepresented minorities.
Shareholders owning at least 5% for one year may recommend board nominees.
Latest events from SINTX Technologies
- Silicon nitride implants disrupt extremity care with infection resistance and rapid market adoption.SINT
LD Micro Invitational XVI15 Jun 2026 - Q1 2025 net loss was $2.3M, but cash nearly doubled as focus shifted to medical devices.SINT
Q1 202512 Jun 2026 - FDA clearance, first product revenue, and cost reductions drive improved results.SINT
Q3 202512 Jun 2026 - 2024 revenue rose 10% to $2.9M, but net loss increased to $11.0M amid restructuring.SINT
Q4 202412 Jun 2026 - Annual meeting to vote on directors, auditor, compensation, and new equity plan.SINT
Proxy filing12 Jun 2026 - Revenue fell sharply as the company pivots to higher-margin medical devices, but liquidity risks persist.SINT
Q4 202512 Jun 2026 - Q2 2024 saw revenue growth, narrowed losses, a reverse split, workforce cuts, and a $4.5M impairment.SINT
Q2 202412 Jun 2026 - Q3 2024 net loss widened due to a $4.5M impairment and workforce reduction amid a strategic review.SINT
Q3 202412 Jun 2026 - Revenue fell 82% year-over-year as the company pivots to biomedical devices amid ongoing losses.SINT
Q2 202512 Jun 2026